Actively Recruiting
SABR for Renal Tumors
Led by University Health Network, Toronto · Updated on 2025-02-20
45
Participants Needed
2
Research Sites
469 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are not suitable candiates for surgery, there is great interest in non-surgical alternatives for kidney cancer treatments. This study will investigate the use of Stereotactic Ablative Radiosurgery (SABR) for renal tumors. SABR is a non-invasive alternative, which involves delivery of high doses of radiation to the target, while minimizing the risk of injury to the surrounding organs. Patients will be seen before and end of treatmetn and will be followed at 4 month intervals for up to 2 years. During the follow ups, patients will be asked to complete a quality of life questionnaire and will have standard of care imaging.
CONDITIONS
Official Title
SABR for Renal Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Solid kidney mass 6 cm or smaller suitable for SABR
- Diagnosis of renal tumor confirmed by histology or imaging
- High risk for surgery or declined surgery to remove kidney tumor
- ECOG performance status of 0 to 3
You will not qualify if you...
- Five or more active metastases
- Systemic therapy (except endocrine therapy) within 6 days before SABR
- Prior abdominal radiotherapy overlapping with kidney causing excessive radiation dose
- End stage renal failure as defined by KDOQI guidelines
- Familial syndromes such as Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC, or Tuber Sclerosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada, L4M 6M2
Not Yet Recruiting
2
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
A
Andrew McPartlin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here